Search Results

You are looking at 101 - 110 of 258 items for :

  • User-accessible content x
Clear All
Free access

Hiranya Pintana, Nattayaporn Apaijai, Nipon Chattipakorn and Siriporn C Chattipakorn

al . 2010 ). In this context, anti-diabetic agents such as rosiglitazone and glucagon-like peptide (GLP-1) have been reported to negate cognitive decline ( During et al . 2003 , Escribano et al . 2009 , Wang et al . 2011 ). Recently developed

Free access

Carmen Sanz, Isabel Roncero, Patricia Vázquez, M Angeles Navas and Enrique Blázquez

glucose concentrations and peptides on GK gene promoter expression was tested in transiently transfected GT1-7 cells. Neither different glucose concentrations (2.8, 5.5, 10, or 20 mM) nor leptin (LEP), glucagon-like peptide 1 (GLP-1) or neuropeptide Y

Free access

Weiwei Xu, Jamie Morford and Franck Mauvais-Jarvis

acting on β cells, to facilitate the effect of testosterone in a paracrine manner. For that reason, we explored the possibility that AR action in β cells amplifies GLP-1R signaling to increase cAMP production. We reasoned that because GLP-1 is secreted by

Restricted access

Xiaoyi Ma, Fei Gao, Qi Chen, Xiuping Xuan, Ying Wang, Hongjun Deng, Fengying Yang and Li Yuan

et al . 2018 ). There were 20–30 islets per mouse examined ( n  = 5–8 mice/group). Table 1 Antibodies for immunodetection. Antibody Source Dilution Guinea pig anti-insulin ab7842, Abcam IF: 1:100 Rabbit anti-GLP

Free access

A Alidibbiat, C E Marriott, K T Scougall, S C Campbell, G C Huang, W M Macfarlane and J A M Shaw

–Aldrich; glucagon-like peptide 1 (7–36) (GLP1) from Bachem (Merseyside, UK) and Betacellulin (BTC) from R&D Systems (Oxon, UK). M-MLV reverse transcriptase, oligo dTs, dNTPs and RNase-free DNase were from Promega; Red Taq polymerase from Sigma–Aldrich and Matrigel

Open access

Yoshinori Kanemaru, Norio Harada, Satoko Shimazu-Kuwahara, Shunsuke Yamane, Eri Ikeguchi, Yuki Murata, Sakura Kiyobayashi, Tomonobu Hatoko and Nobuya Inagaki

test (ITT), and measurement of GIP and GLP-1 content in intestine were evaluated in the second cohort. Energy expenditure, food intake, and gene expression were evaluated in the third cohort. The mice were housed in an air-controlled 25°C room with a

Free access

L M McShane, N Irwin, D O’Flynn, Z J Franklin, C M Hewage and F P M O’Harte

-like peptide-1 (GLP-1), are recognized to account for approximately 50–70% of insulin secretion following a meal ( Nauck et al . 1986 ). However, this incretin contribution to postprandial insulin release falls to less than 20% in T2DM ( Nauck et al. 1986

Restricted access

Flávia Maria Silva-Veiga, Carolline Santos Miranda, Fabiane Ferreira Martins, Julio Beltrame Daleprane, Carlos Alberto Mandarim-de-Lacerda and Vanessa Souza-Mello

inhibitor of dipeptidyl peptidase-4 (DPP-4) that suppresses the rapid degradation of the glucagon-like peptide-1 (GLP-1), a gastrointestinal hormone (incretin) that increases glucose-dependent insulin secretion. DPP-4 inhibitors decrease GLP-1 degradation

Free access

Cho-Rong Bae, Kazuya Hasegawa, Sayaka Akieda-Asai, Yurie Kawasaki, Kazuyo Senba, Youn-Soo Cha and Yukari Date

in the stomach 5 and 10 h after feeding. We monitored plasma levels of the satiety signals cholecystokinin (CCK), glucagon-like peptide 1 (GLP1), and peptide YY (PYY), as well as the levels of glucose and insulin at pre-, mid-, and post-feeding. We

Free access

Yasushi Kirino, Youichi Sato, Takayuki Kamimoto, Kazuyoshi Kawazoe, Kazuo Minakuchi and Yutaka Nakahori

the penultimate L -proline or L -alanine at the N-terminus of several polypeptides, such as glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP; De Meester et al . 2000 ). The major incretin hormones, GLP1 and GIP